BRAIN Biotech AG
XETRA:BNN
Intrinsic Value
The intrinsic value of one BNN stock under the Base Case scenario is 6.61 EUR. Compared to the current market price of 5.66 EUR, BRAIN Biotech AG is Undervalued by 14%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
BNN Profitability Score
Profitability Due Diligence
BRAIN Biotech AG's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
BRAIN Biotech AG's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
BNN Solvency Score
Solvency Due Diligence
BRAIN Biotech AG's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
BRAIN Biotech AG's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
BRAIN Biotech AG
Current Assets | 29.1M |
Other Current Assets | 29.1M |
Non-Current Assets | 46.4M |
Other Non-Current Assets | 46.4M |
Current Liabilities | 19.3M |
Other Current Liabilities | 19.3M |
Non-Current Liabilities | 24.5M |
Other Non-Current Liabilities | 24.5M |
BNN Capital Structure
BRAIN Biotech AG
Market Capitalization | 129M EUR | |
Total Debt | 0 EUR | |
Minority Interest | 0 EUR | |
Preferred Equity | 0 EUR | |
Cash and Equivalents | 0 EUR | |
Short-Term Investments | 0 EUR | |
Enterprise Value | 129M EUR |
Wall St
Price Targets
BNN Price Targets Summary
BRAIN Biotech AG
According to Wall Street analysts, the average 1-year price target for BNN is 13.04 EUR with a low forecast of 7.07 EUR and a high forecast of 18.9 EUR.
Shareholder Return
BNN Return Decomposition
Main factors of price return
is not available
It is impossible to break down the market cap return as the net margin from 5 years ago is negative.
BNN Price
BRAIN Biotech AG
Average Annual Return | -16.33% |
Standard Deviation of Annual Returns | 26.63% |
Max Drawdown | -83% |
Market Capitalization | 129M EUR |
Shares Outstanding | 21 847 500 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. The company is headquartered in Zwingenberg, Hessen and currently employs 293 full-time employees. The company went IPO on 2016-02-09. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.
Contact
IPO
Employees
Officers
The intrinsic value of one BNN stock under the Base Case scenario is 6.61 EUR.
Compared to the current market price of 5.66 EUR, BRAIN Biotech AG is Undervalued by 14%.